Abstract: A novel assay and a suite of devices may isolate nucleic acids from prokaryotic and eukaryotic cells and prepare samples for real-time (quantitative) polymerase chain reaction (PCR) analysis. The assay may employ an aqueous-based non-alcohol approach that yields robust RNA quality. The suite of ready-to-use devices may provide pre-loaded reagents in liquid and lyophilized formats to enable rapid manual operation in a laboratory or remote field environments. The assay and devices may be particularly suitable to analysis in microgravity or deep space environments.

Abstract: The present disclosure provides for identification of recurring transactions to transfer to a financial institution. Potential service providers that may provide services to a user are identified based on received user information. A selection of service providers from a list of the identified potential service providers is received and recurring transactions are identified between the user and the selected service providers. The identified recurring transactions are exported to the financial institution.

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-672 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: PHATFKAMA YKEGTM (42-56) and YQCVQGYRALH (150-160) on CD25. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-634 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-674 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: QCVQGYRA and RWTQPQLICTG on CD25 Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

Abstract: Disclosed herein are various methods and apparatus for performing charge detection mass spectrometry (CDMS). In particular, techniques are disclosed for monitoring a detector signal from a CDMS device to determine how many ions are present in the ion trap (10) of the CDMS device. For example, if no ions are present the measurement can then be terminated early. Similarly, if more than one ion is present, the measurement can be terminated early, or ions can be removed from the trap (10) until only a single ion remains. Techniques are also provided for increasing the probability of there being a single ion in the trap (10). A technique for attenuating an ion beam is also provided.

Abstract: A method of ionising a sample is disclosed comprising nebulising a sample which includes monoclonal antibody (“mAb”) molecules. A stream of monoclonal antibody droplets or charged droplets is directed so as to impact upon a target or electrode so as to form intact parent monoclonal antibody ions, intact minus light chain parent monoclonal antibody ions or light chain (“LC”) fragment monoclonal antibody ions.

Abstract: A mechanism for transferring loads characterized by a frame adapted to be mounted on a lift mechanism of a lift truck, having a pair of telescopic rails mounted at one end to the frame. The telescopic rails extending parallel to one another, extendable laterally of the lift mechanism of the lift truck, between retracted and extended positions by an actuator that moves the telescopic rails. A carriage is mounted on the telescopic rails for movement there along when the telescopic rails are in their extended positions and the free ends of the telescopic rails are supported. The carriage having a secondary lift mechanism mounted thereon by which a load may be raised and lowered relative to the carriage.

Abstract: A data warehouse engine (DWE) includes a central processing unit (CPU) core and a first data organization unit (DOU), where the first DOU is configured to aggregate read operations. The DWE also includes a first command queue coupled between the CPU core and the first DOU, where the first command queue is configured to convey commands from the CPU core to the first DOU.

Abstract: Devices and methods for the efficient disaggregation of tissue samples, separating the tissue into individual intact cells or small aggregates of cells for analysis. A device may include a chamber to receive fluid and a tissue specimen containing more than one cell to be disaggregated. The chamber may include an opening and an agitator in fluid contact with the fluid and the tissue specimen. The agitator may include a micromotor which provides rotational motion to a shaft and an impeller fixed to the shaft such that the impeller and the shaft rotate together upon provision of the rotational motion by the micromotor. The device may include an electrical energy source electrically coupled to the micromotor to rotate the impeller sufficient to disaggregate the one or more individual cells from the tissue specimen and in a manner which does not lyse the one or more individual cells.

Abstract: A computation system-on-a-chip (CSoC) includes a first scalable distributed real-time Data Warehousing (sdrDW) engine and a network interface coupled to the first sdrDW engine, where the network interface is coupled to an interconnect, and where the CSoC is configured to transmit a task request over the interconnect to a first networked bulk storage controller (NBSC) requesting that a task be performed on a bulk storage medium.

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

Abstract: A vehicle attachment apparatus, including an elongated member removably connected to a hitch of a vehicle, an umbrella removably connected to the elongated member to provide shade for a user that is positioned under the umbrella, and a seat attachment removably connected to the elongated member to support the user seated thereupon.

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

Abstract: A mass spectrometer is disclosed comprising a glow discharge device within the initial vacuum chamber of the mass spectrometer. The glow discharge device may comprise a tubular electrode located within an isolation valve, which is provided in the vacuum chamber. Reagent vapour may be provided through the tubular electrode, which is then subsequently ionised by the glow discharge. The resulting reagent ions may be used for Electron Transfer Dissociation of analyte ions generated by an atmospheric pressure ion source. Other embodiments are contemplated wherein the ions generated by the glow discharge device may be used to reduce the charge state of analyte ions by Proton Transfer Reaction or may act as lock mass or reference ions.

Abstract: A method of screening or testing a sample is disclosed that comprises ionising a native human hemoglobin sample to generate parent or precursor ions, subjecting the parent or precursor ions to Electron Transfer Dissociation fragmentation so as to generate a plurality of fragment ions, mass analysing the fragment ions and determining whether or not the fragment ions include fragment ions which are indicative of a variant of hemoglobin.

Abstract: A composition for supporting endogenous systems related to life span, inhibiting mTOR, and reducing damage associated with oxidative phosphorylation. The composition comprises an upregulating compound mixture configured to upregulate an endogenous antioxidant system, an exogenous antioxidant mixture configured to inhibit oxidation of biomolecules by reactive oxygen species, and a mineral mixture configured to provide one or more cofactors to a endogenous antioxidant enzyme. The endogenous antioxidant system includes regulation of mitophagy through mTOR mediated regulation, and a Nrf2 transcription factors that promotes transcription of antioxidant genes.